scholarly journals Modernizing Relationship Therapy through Social Thermoregulation Theory: Evidence, Hypotheses, and Explorations

2017 ◽  
Author(s):  
Hans IJzerman ◽  
Emma C. E. Heine ◽  
Tila M. Pronk
Keyword(s):  
Clinical Trials ◽  
Data Collection ◽  
Randomized Clinical Trials ◽  
Social Contexts ◽  
Emotionally Focused Therapy ◽  
Social Thermoregulation ◽  
Theoretical Perspectives ◽  
Regulation Type ◽  
Emotionally Focused ◽  
Relationship Therapy

In the present article the authors propose to modernize relationship therapy by integrating novel sensor and actuator technologies that can help optimize people’s thermoregulation, especially in social contexts. Specifically, they propose to integrate Social Thermoregulation Theory (IJzerman et al., 2015a; IJzerman & Hogerzeil, 2017) into Emotionally Focused Therapy. As such, the authors suggest to craft a Social Thermoregulation (the pleisiomorphic reliance of relationships on temperature regulation) type therapy to further improve relationship therapy. The authors outline what is known and not known in terms of social thermoregulatory mechanisms, what kind of data collection and analyses are necessary to better understand social thermoregulatory mechanisms, and stress the need to conduct Randomized Clinical Trials prior to implementation. They further warn against too hastily applying these theoretical perspectives. The article concludes by outlining why Social Thermoregulation Therapy is the way forward in improving relationship functioning.This paper was published in Frontiers:IJzerman, H., Heine, E. C., Nagel, S. K., & Pronk, T. M. (2017). Modernizing Relationship Therapy through Social Thermoregulation Theory: Evidence, Hypotheses, and Explorations. Frontiers in Psychology, 8.

L-arginine effect on inflammatory mediators: A systematic review of randomized controlled clinical trials

2019 ◽  
pp. 1-9 ◽  
Author(s):  
Seyed Reza Mirhafez ◽  
Mitra Hariri
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Inflammatory Mediators ◽  
Randomized Clinical Trials ◽  
Randomized Controlled Clinical Trials ◽  
Patients With Cancer ◽  
Reactive Protein ◽  
Randomized Controlled ◽  
Human Adults ◽  
Factor Α

Abstract. L-arginine is an important factor in several physiological and biochemical processes. Recently, scientists studied L-arginine effect on inflammatory mediators such as C-reactive protein (CRP), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). We conducted a systematic review on randomized controlled trials assessing L-arginine effect on inflammatory mediators. We searched data bases including Google scholar, ISI web of science, SCOPUS, and PubMed/Medline up to April 2019. Randomized clinical trials assessing the effect of L-arginine on inflammatory mediators in human adults were included. Our search retrieved eleven articles with 387 participants. Five articles were on patients with cancer and 6 articles were on adults without cancer. L-arginine was applied in enteral form in 5 articles and in oral form in 6 articles. Eight articles were on both genders, two articles were on women, and one article was on men. L-arginine could not reduce inflammatory mediators among patients with and without cancer except one article which indicated that taking L-arginine for 6 months decreased IL-6 among cardiopathic nondiabetic patients. Our results indicated that L-arginine might not be able to reduce selected inflammatory mediators, but for making a firm decision more studies are needed to be conducted with longer intervention duration, separately on male and female and with different doses of L-arginine.

Ongoing randomized clinical trials for the treatment of thrombosis in the antiphospholipid syndrome

2001 ◽  
Vol 21 (02) ◽  
pp. 77-81 ◽  
Author(s):  
G. Finazzi
Keyword(s):  
Clinical Trials ◽  
Large Scale ◽  
Low Dose ◽  
Randomized Clinical Trials ◽  
Oral Anticoagulants ◽  
Collaborative Study ◽  
Clinical Problem ◽  
Vascular Events ◽  
Dose Oral ◽  
Adverse Pregnancy

SummaryThrombotic events are a major clinical problem for patients with antiphospholipid antibodies (APA). However, current recommendations for their prevention and treatment are still based on retrospective studies. Data from large scale, prospective clinical trials are required to ultimately identify the optimal management of these patients. To date, at least four randomized studies are underway. The WAPS and PAPRE clinical trials are aimed to establish the correct duration and intensity of oral anticoagulation in APA patients with major arterial or venous thrombosis. The WARSS-APASS is a collaborative study to evaluate the efficacy and safety of aspirin or low-dose oral anticoagulants in preventing the recurrence of ischemic stroke. The recently announced UK Trial compares low-dose aspirin with or without low-intensity anticoagulation for the primary prevention of vascular events in APA-positive patients with SLE or adverse pregnancy history, but still thrombosis-free. It is hoped that the results of these trials will be available soon since clinicians urgently need more powerful data to treat their patients with the APA syndrome.

Sign in / Sign up

Export Citation Format

Share Document